Harbin Medisan Pharmaceutical Co., Ltd.

002900

CNE1000032V9

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 23:00:00 15/05/2024 BST			5-day change	1st Jan Change
10.04 ^CNY	-0.10%		-4.56%	-26.45%

04-26	Harbin Medisan Pharmaceutical Co., Ltd. Proposes Final Dividend for 2023	CI
04-26	Medisan Pharma's Potassium Chloride Injection Passes Drug Regulator's Evaluation	MT

Harbin Medisan Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022

April 26, 2022 at 09:02 am

Harbin Medisan Pharmaceutical Co., Ltd. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was CNY 256.69 million compared to CNY 230.18 million a year ago. Net loss was CNY 1.17 million compared to net income of CNY 563.3 million a year ago.

Latest news about Harbin Medisan Pharmaceutical Co., Ltd.

Harbin Medisan Pharmaceutical Co., Ltd. Proposes Final Dividend for 2023	04-26	CI
Medisan Pharma's Potassium Chloride Injection Passes Drug Regulator's Evaluation	04-26	MT
Harbin Medisan Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-25	CI
Harbin Medisan Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	26/10/23	CI
Harbin Medisan Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	24/08/23	CI
Harbin Medisan Pharmaceutical Co., Ltd. Approves the Cash Dividend for the Year 2022, Payable on May 31, 2023	17/05/23	CI
Harbin Medisan Pharma Gets Patent Rights of China Pharmaceutical University-Developed Drug	04/05/23	MT
Harbin Medisan Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2022	26/04/23	CI
Harbin Medisan Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	25/04/23	CI
Harbin Medisan Pharmaceutical Co., Ltd. Approves Management Appointments	28/11/22	CI
Harbin Medisan Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	26/10/22	CI
Harbin Medisan Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	25/08/22	CI
Harbin Medisan Pharmaceutical Co., Ltd. Implements Final Cash Dividend for 2021, Payable on June 13, 2022	07/06/22	CI
Harbin Medisan Pharmaceutical Co., Ltd. Approves Final Cash Dividend Proposal for 2021	18/05/22	CI
Harbin Medisan Pharmaceutical Co., Ltd. Announces Final Cash Dividend Proposal for 2021	27/04/22	CI
Harbin Medisan Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	26/04/22	CI
Harbin Medisan Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	26/10/21	CI
Harbin Medisan Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	29/08/21	CI
Harbin Medisan Pharmaceutical Co., Ltd. Announces Final Dividend on A Shares for the Year 2020, Payable on July 5, 2021	29/06/21	CI
Harbin Medisan Pharmaceutical Co., Ltd. Approves Final Cash Dividend for the Year 2020	19/05/21	CI
Harbin Medisan Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2020	28/04/21	CI
Harbin Medisan Pharmaceutical Co., Ltd. Announces Earnings Results for the First Quarter Ended March 31, 2021	27/04/21	CI
Harbin Fuerjia Technology Development Co., Ltd. completed the acquisition of Harbin Beixing Pharmaceutical Co., Ltd from Harbin Medisan Pharmaceutical Co., Ltd..	28/02/21	CI
Harbin Fuerjia Technology Development Co., Ltd. agreed to acquire Harbin Beixing Pharmaceutical Co., Ltd from Harbin Medisan Pharmaceutical Co., Ltd. for CNY 570 million.	09/02/21	CI
Harbin Medisan Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2020	22/10/20	CI

Chart Harbin Medisan Pharmaceutical Co., Ltd.

Duration

Period

Chart Harbin Medisan Pharmaceutical Co., Ltd.

More charts

Company Profile

HARBIN MEDISAN PHARMACEUTICAL CO LTD is a China-based company principally engaged in the research and development, production and sales of chemical preparations, active pharmaceutical ingredients (APIs), medical devices and cosmetics. Its medicines cover the nervous system, cardio-cerebrovascular, systemic anti-infection, musculoskeletal, nutritional infusion, and body fluid balance infusion therapeutic fields. The Company's products include freeze-dried powder injections, small volume injections, large infusion products, solid preparations, medical devices and cosmetics. The Company mainly distributes its products within domestic market.

Sector

Pharmaceuticals

Calendar

22/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
HARBIN MEDISAN PHARMACEUTICAL CO., LTD.	-26.45%	431M
ELI LILLY AND COMPANY	+32.36%	694B
NOVO NORDISK A/S	+29.74%	593B
JOHNSON & JOHNSON	-1.60%	371B
MERCK & CO., INC.	+20.07%	331B
ABBVIE INC.	+6.04%	290B
ASTRAZENECA PLC	+14.55%	239B
ROCHE HOLDING AG	-3.44%	209B
NOVARTIS AG	+10.22%	209B
AMGEN INC.	+9.27%	169B